KR890000408A - 작용화된 폴리아민 킬레이트제, 및 이의 로듐 착화합물 및 이의 제조방법 - Google Patents
작용화된 폴리아민 킬레이트제, 및 이의 로듐 착화합물 및 이의 제조방법 Download PDFInfo
- Publication number
- KR890000408A KR890000408A KR1019880007673A KR880007673A KR890000408A KR 890000408 A KR890000408 A KR 890000408A KR 1019880007673 A KR1019880007673 A KR 1019880007673A KR 880007673 A KR880007673 A KR 880007673A KR 890000408 A KR890000408 A KR 890000408A
- Authority
- KR
- South Korea
- Prior art keywords
- rhodium
- compound
- antibody
- methyl
- carbon atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 229920000768 polyamine Polymers 0.000 title abstract 2
- 150000003283 rhodium Chemical class 0.000 title abstract 2
- 239000002738 chelating agent Substances 0.000 title 1
- 239000010948 rhodium Substances 0.000 claims abstract 41
- 229910052703 rhodium Inorganic materials 0.000 claims abstract 37
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims abstract 36
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 125000002947 alkylene group Chemical group 0.000 claims 13
- -1 aminophenyl Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 239000013522 chelant Substances 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000005647 linker group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 150000002540 isothiocyanates Chemical class 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000000269 nucleophilic effect Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims 2
- QZMNCDCKGNAWSD-UHFFFAOYSA-N 4-(1,4,7,10-tetrazacyclododec-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCNCCNCCNCC1 QZMNCDCKGNAWSD-UHFFFAOYSA-N 0.000 claims 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241001504505 Troglodytes troglodytes Species 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Chemical group 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- KIGIJTPENBPPHQ-UHFFFAOYSA-N n-(2-aminoethyl)-2-[(2-aminoethylamino)methyl]pentane-1,5-diamine Chemical compound NCCNCC(CCCN)CNCCN KIGIJTPENBPPHQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C263/00—Preparation of derivatives of isocyanic acid
- C07C263/10—Preparation of derivatives of isocyanic acid by reaction of amines with carbonyl halides, e.g. with phosgene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
- C07F15/008—Rhodium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
내용 없음
Claims (36)
- 다음 일반식(I)의 화합물(단, 화합물 3-(4-아미노부틸)-1,5,8,12-테트라아자 사이클로테트라데칸은 제외)상기 식에서, R은 각각 독립적으로 탄소수 2 내지 10의 직쇄 또는 측쇄 알킬렌 그룹을 나타내고 단, R그룹에 의해 연결된 2개의 인접한 질소 어느 것에 대해서든 R그룹은 이것이 연결하는 질소들 사이에 적어도 3개의 단일 결합을 제공해야 하며 : R1은 각각 독립적으로 탄소수 1 내지 10의 직쇄 또는 측쇄 알킬렌 그룹 또는 수소를 나타내고 : X 및 X1은 수소이거나, X와 X1이 함께는 탄소수 2 내지 10의 가교 직쇄 또는 측쇄 알킬렌 그룹, 또는 가교 아르알킬렌 그룹(여기에서, 알킬렌은 탄소수 2 내지 10의 직쇄 또는 측쇄 알킬렌 그룹이다)을 형성하며, 단 X와 X1이 함께 형성하는 경우에, X와 X1이 나타내는 그룹은 이것이 연결하는 인접한 질소 사이에 적어도 3개의 단일 결합을 제공해야 하고 : n은 0 또는 1의 정수이며 단, L그룹이 동일 질소원자에 결합되면 n은 0이어야 하고, 만약 그렇지 않으면 n은 1이어야 하며 : y는 1 내지 3의 정수이고 : L은 질소 또는 탄소원자중 어느것에 든지 공유 결합된 링커(linker)/스페이서(spacer) 그룹으로, 질소 또는 탄소원자 상의 한 수소원자와 치환되며, 이때 링커/스페이서 그룹은 다음 일반식으로 표기된다 :[상기 식에서, s는 0 또는 1의 정수이고 : t는 0 내지 20의 정수이며 : R2는 항체 또는 이의 단편에 공유결합할 수 있는 친핵성 또는 친전자정 잔기이거나 항체 또는 이의 단편에 결합될 수 있는 합성 링커이고 : CYc는 지환족 잔기, 방향족 잔기, 지방족 헤테로사이클릭 잔기 또는 방향족 헤테로사이클릭 잔기이며, 이 잔기들은 각각 항체 또는 항체 단편과의 결합을 방해하지 않는 그룹 하나 이상에 의해 임의로 치환된다]
- 제1항에 있어서, L이 다음 일반식을 갖는 화합물 :상기 식에서, R2및 s는 제1항에서 정의한 바와 같고, t는 0 내지 6의 정수이다.
- 제1항 또는 2항에 있어서, R이 탄소수 2 또는 3의 알킬렌 그룹이고 : R1이 수소 또는 메틸이며 : X 및 X1이 수소이거나 X와 X1이 함께 벤질 또는 탄소수 2 또는 3의 알킬렌 그룹을 나타내는 화합물.
- 제3항에 있어서, R2가 이소티오시아네이트, 세미카바자이드, 티오세미카바자이드, 아미노 또는 카복실인 화합물.
- 제4항에 있어서, y가 정수 1인 화합물.
- 제1항에 있어서, 3-[4-(아미노페닐)메틸]-1,5,8,12-테트라아자 사이클로테트라데칸인 화합물.
- 제1항에 있어서, 6-[4-(아미노페닐)메틸]-1,4,8,11-테트라아자 운데칸인 화합물.
- 제1항에 있어서, 6-(3-아미노프로필)-1,4,8,11-테트라아자 운데칸인 화합물.
- 제1항에 있어서, 1,4,7,10-테트라아자-1-[(4-아미노페닐)메틸]사이클로도데칸인 화합물.
- 제1항에 있어서, 3-[4-(아미노페닐)메틸]-1,5,8,12-테트라아자-2,4,9-트리옥소사이클로테트라데칸인 화합물.
- 제1항에 있어서, 3-[4-(아미노페닐)메틸]-1,5,8,12-테트라아자-2,4,9,11-테트라옥소사이클로테트라데칸인 화합물.
- 제1항에 있어서, 6-[4-(아미노페닐)메틸]-1,4,8,11-테트라아자-5,7-디옥소운데칸인 화합물.
- 다음 일반식(I)의 화합물과 착화된 로듐을 포함하는 로듐 착화합물.상기 식에서, R은 각각 독립적으로 탄소수 2 내지 10의 직쇄 또는 측쇄 알킬렌 그룹을 나타내고 단, R그룹에 의해 연결된 2개의 인접한 질소 어느 것에 대해서든 R그룹은 이것이 연결하는 질소들 사이에 적어도 3개의 단일결합을 제공해야 하며 : R1은 각각 독립적으로 탄소수 1 내지 10의 직쇄 또는 측쇄 알킬렌 그룹 또는 수소를 나타내고 : X 및 X1은 수소이거나, X와 X1이 함께는 탄소수 2 내지 10의 가교 직쇄 또는 측쇄 알킬렌 그룹, 또는 가교 아르알킬렌 그룹(여기에서, 알킬렌은 탄소수 2 내지 10의 직쇄 또는 측쇄 알킬렌그룹이다)을 형성하며, 단 X와 X1이 함께 형성하는 경우에, X와 X1이 나타내는 그룹은 이것이 연결하는 인접한 질소 사이에 적어도 3개의 단일 결합을 제공해야 하고 : n은 0 또는 1의 정수이며 단, L그룹이 동일 질소 원자에 결합되면 n은 0이어야 하고, 만약 그렇지 않다면 n은 1이어야 하며 : y는 1 내지 3의 정수이고 : L은 질소 또는 탄소원자중 어느 것에든지 공유 결합된 링커(linker)/스페이서(spacer)그룹으로, 또는 탄소원자상의 한 수소원자와 치환되며, 이때 링커/스페이서 그룹은 다음 일반식으로 표기된다 :[상기 식에서, s는 0 또는 1의 정수이고 : t는 0 내지 20의 정수이며 ; R2는 항체 또는 이의 단편에 공유 결합할 수 있는 칙핵성 또는 친전자성 잔기이거나 항체 또는 이의 단편에 결합될 수 있는 합성 링커이고 : CYc는 지환족 잔기, 방향족 잔기, 지방족 헤테로사이클릭 잔기 또는 방향족 헤테로사이클릭 잔기이며, 이 잔기들은 각각 항체 또는 항체 단편과의 결합을 방해하지 않는 그룹 하나 이상에 의해 임의로 치환된다]
- 제13항에 있어서, L이 하기 일반식을 갖는 제13항에 정의된 일반식(I)의 화합물과 착화된 로듐을 포함하는 로듐 착화합물.상기 식에서, R2는 s는 제13항에서 정의한 바와 같고, t는 0 내지 6의 정수이다.
- 제13항 또는 14항에 있어서, R이 탄소수 2 또는 3의 알킬렌 그룹이고, R1이 수소 또는 메틸이며, X 및 X1은 수소이거나, X와 X1이 함께 벤질 또는 탄소수 2 또는 3의 알킬렌 그룹을 나타내는 제13항에 정의된 일반식(I) 화합물과 착화된 로듐을 포함하는 로듐 착화합물.
- 제15항에 있어서, y가 정수 1인 제12항에 정의된 일반식(I)의 화합물과 착화된 로듐을 포함하는 로듐 착화합물.
- 제15항에 있어서, R2가 이소티오시아네이트, 세미카바자이드, 티오세미카바자이드, 아미노 또는 카복실인 제12항에 정의된 일반식(I)화합물과 착화된 로듐을 포함하는 로듐 착화합물.
- 제13항에 있어서, 3-[4-9아미노페닐)메틸]-1,5,8,12-테트라아자사이클로테트라데칸, 6-[4-(아미노페닐)메틸]-1,4,8,11-테트라아자운데칸, 6-(3-아미노프로필)-1,4,8,11-테트라아자운데칸, 또는 1,4,7,10-테트라아자-1-[(4-아미노페닐)메틸]사이클로도데칸과 착화된 로듐을 포함하는 로듐 착화합물.
- 제13항에 있어서, 3-[4-(아미노페닐)메틸]-1,5,8,12-테트라아자-2,4,9-트리옥소사이클로테트라데칸, 3-[4-(아미노페닐)메틸]-1,5,8,12-테트라아자-2,4,9,11-테트라옥소사이클로테트라데칸, 또는 6-[4-(아미노페닐)메틸]-1,4,8,11-테트라아자-5,7-디옥소운데칸과 착화된 로듐을 포함하는 로듐 착화합물.
- 다음 일반식(Ii)의 로듐 착화합물.[RhChP1P2]A (II)상기 식에서, Rh는 로듐원자를 나타내고 : Ch는 제13항에 정의된 일반식(I)의 화합물을 나타내며 : P1및 P2는 각각 동일하거나 다른 한자리 리간드를 나타내거나, P1과 P2가 함께 2자리 리간드를 나타내고, 단, (a) y가 2이면 P2는 존재하지 않으며, (b) y가 3이면 P1및 P2가 존재하지 않고, A는 로듐 착화합물을 중성으로 만들기에 충분한 전하를 갖는 하나 이상의 음이온을 나타낸다.
- 제13항 또는 제20항에 있어서, 로듐의 적어도 일부가 방사활성 로듐인 로듐 착화합물.
- 제13항 또는 20항에 있어서, 로듐의 적어도 일부가 105Rh인 로듐 착화합물.
- 제20항에 있어서, 화합물이 3-[4-(아미노페닐)메틸]-1,5,8,12-테트라아자사이클로테트라데칸, 6-[4-(아미노페닐)메틸]-1,4,8,11-테트라아자운데칸, 6-(3-아미노프로필)-1,4,8,11-테트라아자운데칸, 또는 1,4,7,10-테트라아자-1-[(4-아미노페닐)메틸]사이클로도데칸인 로듐 착화합물.
- 제20항에 있어서, [Rh(BA-2,3,2-tet)Cl2]Cl·HCl 또는 [Rh(BA-사이클람)Cl2]Cl·HCl인 로듐 착화합물.
- 제13항에 있어서, 중합성 지지체에 공유 결합된 로듐 착화합물.
- 항체 또는 항체 단편에 공유 결합된 제21항 또는 22항의 로듐 착화합물을 포함하는 로듐 킬레이트/항체 결합물.
- 제25항에 있어서, 항체 또는 항체 단편이 B72.3, CC-49 또는 CC-49(Fab′)2인 로듐 킬레이트/항체 결합물.
- 제26항에 있어서, 항체 또는 항체 단편이 모노클로날 항체 또는 이의 단편인 로듐 킬레이트/항체 결합물.
- 제26항의 로듐 길레이트/항체 결합물 및 약제학적으로 허용되는 담체를 포함하는 로듐 킬레이트/항체 조성물.
- 제29항에 있어서, 약제학적으로 허용되는 담체가 액체인 로듐 킬레이트/항체 조성물.
- 제26,27,28 또는 29항의 조성물을 투여하여 포유류의 질환상태를 진단 또는 치료하는 방법.
- 제31항에 있어서, 질환상태가 암인 방법.
- 진단 또는 치료에 사용하기 위한 제26항, 27항 또는 28항의 로듐 킬레이트/항체 결합물.
- 진단 또는 치료에 사용하기 위한 제29항의 로듐 킬레이트/항체 조성물.
- Rh A·nH2O(여기에서, A 및 n은 이하에서 정의하는 바와 같다)를 ChP1P2(여기에서, Ch, P1및 P2는 이하에서 정의하는 바와 같다)와 반응시키는 것을 포함하여 일반식(II)의 로듐 착화합물을 제조하는 방법.[RhChP1P2]A (II)상기 식에서, Rh는 로듐원자이고 : Ch는 제13항에 정의된 일반식(I)의 화합물을 나타내며 : P1및 P2는 각각 동일하거나 다른 한자리 리간드이거나, P1과 P2가 함께 2자리 리간드(P1, P2)를 나타내고, 단, 제13항에 정의된 일반식(I)에서 y가 2이면 P2는 존재하지 않으며, y가 3이면 P1및 P2는 존재하지 않고 : A는 착화합물을 중성으로 하기에 충분한 전하를 갖는 음이온 하나 이상을 나타내며 : n은 0 내지 수화물을 형성하기에 필요한 수이다.
- 제35항에 있어서, 반응을 수용액중, 약 pH7에서 환류하에 수행하는 방법.※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019970010765A KR0132614B1 (ko) | 1987-06-24 | 1997-03-27 | 작용화된 폴리아민 킬레이트제, 및 이의 로듐 착화합물 및 이의 제조방법 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/065,739 US4994560A (en) | 1987-06-24 | 1987-06-24 | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US065,739 | 1987-06-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR890000408A true KR890000408A (ko) | 1989-03-14 |
| KR970011005B1 KR970011005B1 (ko) | 1997-07-05 |
Family
ID=22064774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880007673A KR970011005B1 (ko) | 1987-06-24 | 1988-06-24 | 작용화된 폴리아민 킬레이트제, 및 이의 로듐 착화합물 및 이의 제조방법 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US4994560A (ko) |
| EP (1) | EP0296522B1 (ko) |
| JP (1) | JP2728437B2 (ko) |
| KR (1) | KR970011005B1 (ko) |
| CN (1) | CN1022839C (ko) |
| AT (1) | ATE143364T1 (ko) |
| CA (1) | CA1341349C (ko) |
| DE (1) | DE3855564T2 (ko) |
| DK (1) | DK343288A (ko) |
| ES (1) | ES2091746T3 (ko) |
| FI (1) | FI101378B (ko) |
| GR (1) | GR3021537T3 (ko) |
| HK (1) | HK1006168A1 (ko) |
| HU (1) | HU201333B (ko) |
| IL (1) | IL86835A (ko) |
| NO (1) | NO178928C (ko) |
| NZ (1) | NZ225070A (ko) |
| PT (1) | PT87802B (ko) |
| ZA (1) | ZA884545B (ko) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132409A (en) * | 1987-01-12 | 1992-07-21 | Bracco Industria Chimica S.P.A. | Macrocyclic chelating agents and chelates thereof |
| US5006643A (en) * | 1987-06-24 | 1991-04-09 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
| ZA894792B (en) * | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
| US5756065A (en) * | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| CA1341373C (en) * | 1988-06-24 | 2002-07-02 | Roberta C. Cheng | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| WO1990007261A2 (en) * | 1988-12-22 | 1990-07-12 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
| BR8907282A (pt) * | 1988-12-23 | 1991-03-12 | Dow Chemical Co | Processo para preparar complexos de metal funcionalizados com isotiocianato |
| US5808003A (en) * | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5292868A (en) * | 1989-05-26 | 1994-03-08 | Akzo N.V. | Chelating agents for attaching metal ions to proteins |
| DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
| CA2072080A1 (en) * | 1990-01-19 | 1991-07-20 | Jo Klaveness | Chelating compounds |
| AU7587091A (en) * | 1990-03-26 | 1991-10-21 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | A fonctionalized complexand |
| US5283293A (en) * | 1990-12-14 | 1994-02-01 | Corvas, Inc. | Reagents for automated synthesis of peptide analogs |
| GB9105489D0 (en) * | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
| DE4140779A1 (de) * | 1991-12-06 | 1993-06-09 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Verfahren zur herstellung von mono-n-substituierten tetraazamakrocyclen |
| US5410043A (en) * | 1991-12-06 | 1995-04-25 | Schering Aktiengesellschaft | Process for the production of mono-N-substituted tetraaza macrocycles |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| WO1993020852A2 (en) * | 1992-04-13 | 1993-10-28 | The Dow Chemical Company | Macrocyclic chelating agents, chelates and conjugates thereof |
| US5310535A (en) * | 1992-04-24 | 1994-05-10 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
| DE4218744C2 (de) * | 1992-06-04 | 1997-11-06 | Schering Ag | Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe |
| EP0588229A3 (en) * | 1992-09-12 | 1994-06-15 | Hoechst Ag | Macrocyclic chelating agents for the preparation of technetium or rhenium complexes |
| WO1995026206A1 (en) * | 1994-03-28 | 1995-10-05 | The Regents Of The University Of California | Method for preparing radionuclide-labeled chelating agent-ligand complexes |
| HUT76318A (en) * | 1994-04-22 | 1997-08-28 | Searle & Co | Diagnostic image analysis with metal complexes |
| EP0757694A4 (en) * | 1994-04-29 | 1998-05-06 | Univ Missouri | THIOETHER COMPOUNDS FOR THE PREPARATION OF BIFUNCTIONAL CHELATING AGENTS FOR THERAPEUTIC RADIOPHARMACEUTICALS |
| US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US5663161A (en) | 1995-02-17 | 1997-09-02 | The Research Foundation Of State University Of New York | Anti-viral triaza compounds |
| US5719033A (en) * | 1995-06-28 | 1998-02-17 | Motorola, Inc. | Thin film transistor bio/chemical sensor |
| WO1997001520A1 (en) * | 1995-06-28 | 1997-01-16 | E.I. Du Pont De Nemours And Company | Composition and method for stabilizing radiolabeled organic compounds |
| BR9610241A (pt) | 1995-08-17 | 1999-06-29 | Monsanto Co | Processos para análise de imagem de diagnóstico utilizando bioconjgados de complexos de metal de ligandos macrocíclicos contendo nitrogênio |
| US5871436A (en) * | 1996-07-19 | 1999-02-16 | Advanced Cardiovascular Systems, Inc. | Radiation therapy method and device |
| US5782740A (en) * | 1996-08-29 | 1998-07-21 | Advanced Cardiovascular Systems, Inc. | Radiation dose delivery catheter with reinforcing mandrel |
| US6143849A (en) * | 1996-11-27 | 2000-11-07 | The United States Of America As Represented By The Secretary Of The Navy | Synthesis of acrylate and alkyl acrylate monomers and polymers of chelators |
| US6776792B1 (en) * | 1997-04-24 | 2004-08-17 | Advanced Cardiovascular Systems Inc. | Coated endovascular stent |
| US6210312B1 (en) | 1997-05-20 | 2001-04-03 | Advanced Cardiovascular Systems, Inc. | Catheter and guide wire assembly for delivery of a radiation source |
| US6159139A (en) * | 1998-02-17 | 2000-12-12 | Advanced Cardiovascular Systems Inc. | Radiation delivery catheter with a spring wire centering mechanism |
| US6224535B1 (en) | 1998-02-17 | 2001-05-01 | Advanced Cardiovascular Systems, Inc. | Radiation centering catheters |
| US6159140A (en) * | 1998-02-17 | 2000-12-12 | Advanced Cardiovascular Systems | Radiation shielded catheter for delivering a radioactive source and method of use |
| US6235363B1 (en) | 1998-05-06 | 2001-05-22 | Avery Dennison Corporation | Composite construction containing barrier layer |
| AU3501700A (en) | 1999-02-26 | 2000-09-14 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
| US6582417B1 (en) | 1999-09-22 | 2003-06-24 | Advanced Cardiovascular Systems, Inc. | Methods and apparatuses for radiation treatment |
| US6605031B1 (en) | 1999-09-22 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stepped centering balloon for optimal radiation delivery |
| US7994449B2 (en) | 2000-02-16 | 2011-08-09 | Advanced Cardiovascular Systems, Inc. | Square-wave laser bonding |
| US7163504B1 (en) | 2000-02-16 | 2007-01-16 | Advanced Cardiovascular Systems, Inc. | Multi-lumen fluted balloon radiation centering catheter |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| EP1294949A4 (en) | 2000-06-15 | 2004-08-25 | Human Genome Sciences Inc | HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON |
| KR101287395B1 (ko) | 2000-06-16 | 2014-11-04 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| US6783793B1 (en) * | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
| US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
| MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
| US7862495B2 (en) * | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
| US6565659B1 (en) * | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
| US6656216B1 (en) * | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
| EP1411918B1 (en) | 2001-07-31 | 2011-12-28 | Genzyme Global S.à.r.l. | Methods to mobilize progenitor/stem cells |
| CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| EP1497445A2 (en) * | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| US7371383B2 (en) | 2002-04-12 | 2008-05-13 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
| NZ537579A (en) * | 2002-06-10 | 2006-10-27 | Vaccinex Inc | C35 peptide epitopes and their analogs |
| US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
| AU2003302254A1 (en) * | 2002-12-16 | 2004-07-22 | Avery Dennison Corporation | Analyte detecting article and method |
| US7198675B2 (en) * | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| NZ547591A (en) * | 2003-12-04 | 2009-11-27 | Vaccinex Inc | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US7563324B1 (en) | 2003-12-29 | 2009-07-21 | Advanced Cardiovascular Systems Inc. | System and method for coating an implantable medical device |
| NZ548612A (en) | 2004-02-09 | 2009-11-27 | Human Genome Sciences Inc | Albumin fusion proteins comprising tandem GLP-1 |
| US7973139B2 (en) * | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| US7553377B1 (en) | 2004-04-27 | 2009-06-30 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for electrostatic coating of an abluminal stent surface |
| US20050288481A1 (en) * | 2004-04-30 | 2005-12-29 | Desnoyer Jessica R | Design of poly(ester amides) for the control of agent-release from polymeric compositions |
| US7632307B2 (en) | 2004-12-16 | 2009-12-15 | Advanced Cardiovascular Systems, Inc. | Abluminal, multilayer coating constructs for drug-delivery stents |
| US20060216431A1 (en) * | 2005-03-28 | 2006-09-28 | Kerrigan Cameron K | Electrostatic abluminal coating of a stent crimped on a balloon catheter |
| ES2561628T3 (es) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
| US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
| US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
| MX2008011905A (es) | 2006-03-21 | 2008-09-30 | Genentech Inc | Terapia de combinacion. |
| US8003156B2 (en) * | 2006-05-04 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
| US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
| US8048448B2 (en) * | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
| US20080305111A1 (en) * | 2006-06-22 | 2008-12-11 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
| US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
| WO2008028192A2 (en) | 2006-09-01 | 2008-03-06 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| WO2008105473A1 (ja) * | 2007-02-28 | 2008-09-04 | National University Corporation Chiba University | 抗悪性腫瘍薬 |
| US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
| CN101970488B (zh) | 2007-12-07 | 2014-06-18 | 津莫吉尼蒂克斯公司 | 对il-31特异的人源化抗体分子 |
| EP2237792B1 (en) | 2007-12-26 | 2017-05-24 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| AU2009335000B2 (en) | 2008-12-30 | 2014-11-13 | Children's Medical Center Corporation | Method of predicting acute appendicitis |
| RU2011142974A (ru) | 2009-03-25 | 2013-04-27 | Дженентек, Инк. | НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ |
| CN102666473B (zh) * | 2009-10-08 | 2014-04-23 | 安格斯化学公司 | 低voc多胺 |
| US20110293629A1 (en) | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| GB201008584D0 (en) * | 2010-05-22 | 2010-07-07 | Univ Warwick | Novel iridium anti-cancer compounds |
| US10384078B2 (en) * | 2013-10-15 | 2019-08-20 | Ip Liberty Vision Corporation | Polymeric radiation-sources |
| ES2905777T3 (es) | 2014-05-30 | 2022-04-12 | Shanghai Henlius Biotech Inc | Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR) |
| EP3029032A1 (en) * | 2014-12-05 | 2016-06-08 | Centre National de la Recherche Scientifique (CNRS) | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof |
| SG10201913158PA (en) | 2015-04-03 | 2020-02-27 | Eureka Therapeutics Inc | Constructs targeting afp peptide/mhc complexes and uses thereof |
| CA2980189A1 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| AU2017327828B2 (en) | 2016-09-16 | 2023-11-16 | Shanghai Henlius Biotech, Inc. | Anti-PD-1 antibodies |
| TW201831517A (zh) | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | 靶向組織蛋白h3肽/mhc複合體之構築體及其用途 |
| AU2018258049A1 (en) | 2017-04-26 | 2019-12-12 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| AU2019235033A1 (en) | 2018-03-14 | 2020-07-30 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| CA3103936A1 (en) | 2018-06-18 | 2019-12-26 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2803528C2 (de) | 1977-03-09 | 1984-10-18 | Tabushi, Iwao, Kyoto | Schwermetallionen-Adsorbens und dessen Verwendung zum Adsorbieren von Schwermetallionen |
| US4622420A (en) * | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
| US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| US4479930A (en) * | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4615876A (en) * | 1983-04-25 | 1986-10-07 | Curators Of The University Of Missouri | Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides |
| US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
| US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
| US5057302A (en) * | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
| US5006643A (en) * | 1987-06-24 | 1991-04-09 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
-
1987
- 1987-06-24 US US07/065,739 patent/US4994560A/en not_active Expired - Fee Related
-
1988
- 1988-06-15 CA CA000569508A patent/CA1341349C/en not_active Expired - Fee Related
- 1988-06-17 NZ NZ225070A patent/NZ225070A/xx unknown
- 1988-06-20 EP EP88109799A patent/EP0296522B1/en not_active Expired - Lifetime
- 1988-06-20 ES ES88109799T patent/ES2091746T3/es not_active Expired - Lifetime
- 1988-06-20 AT AT88109799T patent/ATE143364T1/de not_active IP Right Cessation
- 1988-06-20 DE DE3855564T patent/DE3855564T2/de not_active Expired - Fee Related
- 1988-06-22 IL IL8683588A patent/IL86835A/en not_active IP Right Cessation
- 1988-06-22 DK DK343288A patent/DK343288A/da not_active Application Discontinuation
- 1988-06-23 HU HU883188A patent/HU201333B/hu not_active IP Right Cessation
- 1988-06-23 PT PT87802A patent/PT87802B/pt not_active IP Right Cessation
- 1988-06-23 NO NO882784A patent/NO178928C/no not_active IP Right Cessation
- 1988-06-23 FI FI883046A patent/FI101378B/fi not_active IP Right Cessation
- 1988-06-24 ZA ZA884545A patent/ZA884545B/xx unknown
- 1988-06-24 KR KR1019880007673A patent/KR970011005B1/ko not_active IP Right Cessation
- 1988-06-24 JP JP63155058A patent/JP2728437B2/ja not_active Expired - Fee Related
- 1988-06-24 CN CN88104543A patent/CN1022839C/zh not_active Expired - Fee Related
-
1990
- 1990-11-28 US US07/619,153 patent/US5284644A/en not_active Expired - Lifetime
-
1996
- 1996-11-06 GR GR960402911T patent/GR3021537T3/el unknown
-
1998
- 1998-06-13 HK HK98105268A patent/HK1006168A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890000408A (ko) | 작용화된 폴리아민 킬레이트제, 및 이의 로듐 착화합물 및 이의 제조방법 | |
| US6180620B1 (en) | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals | |
| Boros et al. | Macrocycle‐based hydroxamate ligands for complexation and immunoconjugation of 89zirconium for positron emission tomography (PET) imaging | |
| KR920700205A (ko) | 트리-아자 마크로싸이클 화합물과 이들의 금속착화합물 | |
| AU2003239952B2 (en) | Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same | |
| US5804161A (en) | Contrast agents | |
| Safo et al. | Models of the Cytochromes. Axial Ligand Orientation and Complex Stability in Iron (II) Porphyrinates: The Case of the Noninteracting dπ Orbitals | |
| US5101041A (en) | Triamines and their derivatives as bifunctional chelating agents | |
| JPS63290854A (ja) | 二官能性キレート化剤 | |
| CA2079212A1 (en) | Contrast media | |
| JPH08502240A (ja) | 二官能性キレート剤としての置換チオ尿素 | |
| JPS62502618A (ja) | 金属キレ−トたんぱく質接合体の形成方法 | |
| Speca et al. | Purine complexes with divalent 3d metal perchlorates | |
| KR960704864A (ko) | 디키런트로서의 폴리아자시클로알칸 (polyazacycloalkanes as dischelants) | |
| JPH06506449A (ja) | コントラスト媒体 | |
| IE74849B1 (en) | Protein labelling | |
| PT701440E (pt) | Complexos tri(platinicos) | |
| CA2103553A1 (en) | Bicyclopolyazamacrocyclocarboxylic acid complexes their conjugates, processes for their preparation, and use as radiopharmaceuticals | |
| Tweedy | DESIGN, SYNTHESIS, AND STUDY OF A TOTALLY SYNTHETIC HEME-PROTEIN MODEL CONTAINING AN APPENDED BASE | |
| KR0132614B1 (ko) | 작용화된 폴리아민 킬레이트제, 및 이의 로듐 착화합물 및 이의 제조방법 | |
| JPH0454165A (ja) | 新規複素環化合物 | |
| Bauer | A Waldenström macroglobulin which binds 3-amino-2, 4, 6-triiodobenzoic acid—II: Cross reactions of mono-and divalent compounds | |
| Rasmussen | Synthesis of bifunctional azamacrocycles for radiometal chelation and antibody conjugation | |
| NZ239845A (en) | Rhodium complexes, conjugates with antibodies or antibody fragments, and pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20020909 Year of fee payment: 6 |
|
| LAPS | Lapse due to unpaid annual fee |